FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Amkr: Results/outlook Ahead Of Consensus, Supported By Auto/industrial Recovery

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Q1 sales of $1.68B (+27% Y/Y) exceeded Street expectations ($1.65B) along with EPS of $0.33 (vs. Street $0.24), with Q2 revenue/EPS guidance of $1.80B/$0.47 representing larger beats vs. expectations of $1.74B/$0.31, respectively. Q2 gross margin was guided to 15.0%, above consensus of 14.8%. We point to Auto/Industrial strength as the most important result during Q1, with the segment's 28% Y/Y growth continuing to show acceleration over the past several quarters following a long period of weakness. Tariff reductions should help, though emerging issues like the Strait of Hormuz closure and ongoing memory shortage could challenge this recovery thesis in the coming quarters. AMKR lowered its 2026 capex outlook slightly from ~$3.0B to ~$2.75B, a total that remains substantial as it looks to support TSMC's ambitions in Arizona, which will likely necessitate borrowing/higher interest costs. We consider the reduced capex forecast to reflect a narrowing of expectations rather than lower demand projections.

相關文章

International

日本3月失業率小幅上升至2.7%。

根據日本政府週二公佈的數據,日本失業率3月小幅上升至2.7%,高於上月的2.6%。 數據顯示,經季節性調整後,3月就業人數從2月的6,827萬人略微下降至6,815萬人,而失業人數則從上月的185萬人增加至186萬人。

$^N225
Asia

市場傳聞:受美國定價模式影響,日本或將錯失新藥供應

根據《日經新聞》週二報道,由於美國一項定價模式可能將美國藥品價格與日本在最惠國待遇(MFN)下的較低價格掛鉤,日本或將錯失突破性藥物。 該報稱,根據這項計劃,美國將參考包括日本在內的其他國家的藥品價格來確定聯邦醫療保險(Medicare)和醫療補助(Medicaid)的報銷標準,但企業可以透過不在日本上市產品來規避這一限制。 該報指出,這可能導致製藥公司推遲或放棄進入日本市場,而日本則可能面臨藥品價格上漲和社會保險成本增加的壓力。 報導稱,產業組織正在敦促日本重新評估其定價規則,以使創新藥物的價格與國際水準接軌,並在專利期間維持這一水準。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊被認為是來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)

$^N225
Asia

Echo IQ 將基於人工智慧的決策支援軟體部署到美國醫療系統中

根據週二提交給澳洲證券交易所的文件顯示,Echo IQ(ASX:EIQ)已將其基於人工智慧的決策支援軟體EchoSolv AS部署到紐約西奈山醫療系統,用於評估嚴重主動脈瓣狹窄。 文件也指出,該公司正繼續與美國其他醫院洽談該產品的潛在應用機會。

$ASX:EIQ